Synacor Names Steve Oroszlan Vice President of Business

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Synacor Names Steve Oroszlan Vice President of Business Development

BUFFALO, N.Y., July 2, 2014 (GLOBE NEWSWIRE) -- Synacor Inc. (Nasdaq: SYNC ), the leading provider of next-gen startpages, homescreens, award-winning TV Everywhere solutions and cloud-based Identity Management (IDM) services, across multiple devices for cable, satellite, telecom and consumer electronics companies in the U.S. and abroad, today announced the appointment of Steve Oroszlan to Vice President of Business Development. In this role, Oroszlan will be responsible for developing new business and selling into new verticals, expanding Synacor's reach and creating new revenue streams for the company, especially distribution for Synacor's new Mobile Homescreen business.

Prior to Synacor, Oroszlan served as Director of Business Development for Microsoft Corporation, where he was responsible for generating digital advertising revenue from syndication, licensing and technology partnerships. Oroszlan holds a Bachelors degree in Economics and Political Science from the University of Pennsylvania and an MBA from London Business School in the UK.

"The timing is perfect for Synacor to enter new verticals, especially with its next-gen consumer experiences for TV Everywhere, authentication, search & discovery, and wi-fi, as well as the company's escalation in Android," said Oroszlan. "I'm thrilled to put my expertise and connections to work on behalf of generating new market opportunities and revenue streams for Synacor, especially its new Mobile Homescreen business."

"At Synacor, attracting the best and the brightest talent is priority one, and we're elated to have Steve Oroszlan join our leadership team with his specialized skills in developing new channels and revenue opportunities. Steve's bizdev depth and proven track record will be tremendous assets to Synacor," said Synacor Co-Founder George Chamoun. "Steve already has gained great traction for Synacor."

About Synacor

Synacor's white-label platform enables cable, satellite, telecom and consumer electronics companies to deliver TV Everywhere, digital entertainment, cloud-based services and apps to their end-consumers across multiple devices, strengthening those relationships while monetizing the engagement. In addition, Synacor offers digital ad inventory for brands wanting a customized, targeted, programmatic means of reaching their audiences. Synacor (Nasdaq: SYNC ) is headquartered in Buffalo, NY, with tech hubs in Toronto, Ottawa and Boston , and ad sales offices in New York, Detroit and Los Angeles. For more information, visit synacor.com .

All Media. One Place. Any Device.

Forward-Looking Statements

This release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of management of Synacor, and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other factors affecting the operation of the respective businesses of Synacor. More detailed information about these factors may be found in filings by Synacor, as applicable, with the Securities and Exchange Commission, including their respective Quarterly Report on Form 10-Q. Synacor is under no obligation to, and expressly disclaims any such obligation to, update or alter their respective forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact: Meredith Roth VP, Corporate Communications Synacor 646-380-5141

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles